OSTAGI®-D3

Composition: Each tablet contains:
Alendronic acid . . . . . . . . . . . . . . . . . . . . . . . . 70 mg
(as sodium alendronate trihydrate . . . . . . . . .91.35 mg)
Cholecalciferol . . . . . . . . . . . . . . . . . . . . .. .2,800 IU
(as Cholecalciferol oily solution 1 M.IU/ g . . . . . 2.8 mg)
Presentation:
1 blister of 4 tablets in a carton box.
Indications:
Ostagi-D3 is indicated for the treatment of osteoporosis in postmenopausal women, the treatment of osteoporosis in men. Ostagi-D3 increases bone mass and prevents fractures, including those of the hip, wrist and spine (vertebral compression fractures) and vitamin D supplementation to the body.
Prevention and treatment of corticosteroid-induced osteoporosis.
Paget’s disease treatment: Paget’s disease where the level of serum alkaline phosphatase is at least twice upper limit of normal, in those who are symptomatic, or who are at risk for future complications of disease.

error: Không được phép!